Literature DB >> 12897408

Does proteasome inhibition play a role in mediating neuropathology and neuron death in Alzheimer's disease?

Qunxing Ding1, Jeffrey N Keller.   

Abstract

An increasing number of studies have demonstrated evidence that inhibition of proteasome activity may play a causal role in mediating the neuropathology and neuron death observed in Alzheimer's disease (AD). These reports have clearly demonstrated that proteasome inhibition occurs in the AD brain, with numerous in vitro and in vivo studies elucidating the ability of proteasome inhibitors to induce AD-like neuropathology and even neuron death. In spite of these clear and significant findings, several important questions regarding the role of proteasome inhibition in AD remain unanswered. We propose that chronic low-level proteasome inhibition, but not severe and acutely toxic levels of proteasome inhibition, likely plays a role in mediating specific aspects of AD neuropathology. Experimental evidence supporting this hypothesis, as well as the scientific implications of this hypothesis are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12897408     DOI: 10.3233/jad-2003-5307

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

Review 1.  Oxidative imbalance in Alzheimer's disease.

Authors:  Xiongwei Zhu; Hyoung-Gon Lee; Gemma Casadesus; Jesus Avila; Kelly Drew; George Perry; Mark A Smith
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

2.  Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions.

Authors:  Tilman Grune; Diana Botzen; Martina Engels; Peter Voss; Barbara Kaiser; Tobias Jung; Stefanie Grimm; Gennady Ermak; Kelvin J A Davies
Journal:  Arch Biochem Biophys       Date:  2010-05-15       Impact factor: 4.013

3.  Establishment of a suite of assays that support the discovery of proteasome stimulators.

Authors:  Darci J Trader; Scott Simanski; Paige Dickson; Thomas Kodadek
Journal:  Biochim Biophys Acta Gen Subj       Date:  2017-01-05       Impact factor: 3.770

4.  Genetic and pharmacologic proteasome augmentation ameliorates Alzheimer's-like pathology in mouse and fly APP overexpression models.

Authors:  E Sandra Chocron; Erin Munkácsy; Harper S Kim; Przemyslaw Karpowicz; Nisi Jiang; Candice E Van Skike; Nicholas DeRosa; Andy Q Banh; Juan P Palavicini; Paweł Wityk; Leszek Kalinowski; Veronica Galvan; Pawel A Osmulski; Elzbieta Jankowska; Maria Gaczynska; Andrew M Pickering
Journal:  Sci Adv       Date:  2022-06-08       Impact factor: 14.957

5.  Activation of PERK kinase in neural cells by proteasome inhibitor treatment.

Authors:  Le Zhang; Philip J Ebenezer; Kalavathi Dasuri; Annadora J Bruce-Keller; Sun Ok Fernandez-Kim; Ying Liu; Jeffrey N Keller
Journal:  J Neurochem       Date:  2009-10-24       Impact factor: 5.372

6.  UCHL1 and Proteasome in Blood Serum in Relation to Dietary Habits, Concentration of Selected Antioxidant Minerals and Total Antioxidant Status among Patients with Alzheimer's Disease.

Authors:  Sylwia Bogdan; Anna Puścion-Jakubik; Katarzyna Klimiuk; Katarzyna Socha; Jan Kochanowicz; Ewa Gorodkiewicz
Journal:  J Clin Med       Date:  2022-01-14       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.